Light exercise boosts brain blood flow in children, study finds
Waseda University research suggests short bursts of exercise can enhance children's cognitive functions
Children around the world have been shown to insufficiently engage in physical exercise (Photo for representation: iStock)
By Eastern EyeAug 27, 2024
ENGAGING in light-intensity exercises for a short duration significantly improves blood flow to the cerebrum in children, which is known to enhance cognitive functions, according to a recent study by Waseda University in Japan.
The study involved 41 healthy children ranging from fifth-grade elementary to third-year junior high school students to explore the effects of brief, light exercises on the prefrontal cortex, a part of the brain associated with cognitive processes.
Researchers focused on simple exercises that can be easily performed without special equipment, such as seated stretches, with movements lasting between 10 to 20 seconds.
Using functional near-infrared spectroscopy, a technique that measures changes in brain blood flow by analysing oxyhaemoglobin levels, the team observed a significant increase in blood flow to multiple regions of the prefrontal cortex during all forms of exercise compared to resting states.
The findings, published in the journal Scientific Reports, suggest that incorporating these types of exercises could enhance children's cognitive abilities and may also serve as a strategy to prevent cognitive decline in adults and the elderly.
"By combining these exercises, it is possible to develop a program that everyone can easily engage in to improve children's executive functions," said Takashi Naito, a doctoral student at Waseda University and one of the study's authors.
The authors further wrote that the study implies that short-duration, light-intensity exercises, provided that they entail a certain degree of cognitive and/or physical demands, can activate the prefrontal cortex and increase blood flow.
Previous studies have shown that physical exercise improves cognitive function in many ways such as by improving blood flow to the brain, by causing structural changes in the brain and by promoting the forming of new brain cells, or neurons.
However, as children around the world have been shown to insufficiently engage in physical exercise, leading to high levels of sedentary behaviour, the authors said that the study's results offer potential solutions.
The study is a significant step forward in combating sedentary lifestyles and activating brain functions in children, thereby supporting their physical and mental growth, they said.
"Our goal is to develop a light-intensity exercise program that is accessible to everyone, aiming to enhance brain function and reduce children's sedentary behaviour," Naito said. (PTI)
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.